SCHEMBL562152

SCHEMBL562152

CCCCCc1cc2c(nc(O)n2CCCCS(C)(=O)=O)c(N(Cc2ccc(OC)cc2)Cc2ccc(OC)cc2)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CNR2 P34972 3/20 0.35
PTGS2 P35354 1/20 0.34
HRH2 P25021 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
KCNH2 Q12809 3/20 0.34
PDE4B Q07343 1/20 0.33
SMPD1 P17405 1/20 0.33
TLR8 Q9NR97 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
USP2 O75604 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CASP3 P42574 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563162 0.90 PTGS2 (0.33) PTGS2LMNAAPLNR
SCHEMBL562921 0.84 KCNH2 (0.41) TP53MAPTSMN1; SMN2KCNH2SMPD1
SCHEMBL563383 0.82 TLR7 (0.45) TP53MAPTSMN1; SMN2RXFP1TLR7
SCHEMBL562449 0.82 TLR7 (0.40) TP53MAPTSMN1; SMN2CNR2PTGS2
SCHEMBL563312 0.81 DYRK1A (0.43) MAPTCNR2
SCHEMBL561914 0.78 TLR7 (0.39) TLR7USP2LMNACYP1A2CYP2D6
SCHEMBL562256 0.78 KCNH2 (0.37) CNR2KCNH2TLR7CYP2D6CYP2C9
SCHEMBL563140 0.78 TLR7 (0.44) TP53MAPTSMN1; SMN2TLR8TLR7
SCHEMBL3339558 0.75 SLC2A1 (0.42) TP53LMNATSHR
SCHEMBL561529 0.75 TP53 (0.38) TP53TLR7USP2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods PFIZER INC. (US) 2012-02-09 US disclosed
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 TP53 221/4885MAPT 4506/4885SMN1; SMN2 2868/4885
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods IL2, IL4, IL4I1 TP53 196/4885MAPT 4506/4885SMN1; SMN2 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.